The global peptide therapeutics market size was estimated at USD 49.13 billion in 2024 and is projected to be worth around USD 83.75 billion by 2034, growing at a CAGR of 5.47% from 2025 to 2034.
Highlights of the Peptide Therapeutics Market
- North America dominated the global market in 2024.
- Europe is anticipated to grow at the fastest rate in the market during the forecast period.
- By application, the metabolic disorder segment held a dominant presence in the market in 2024.
- By application, the cancer segment is expected to grow at the fastest rate in the market during the forecast period of 2025 to 2034.
- By type, the innovative segment accounted for a considerable share of the market in 2024.
- By type, the generic segment is projected to experience the highest growth rate in the market between 2025 and 2034.
- By route of administration, the parenteral segment led the market.
- By route of administration, the oral segment is set to experience the fastest rate of market growth from 2025 to 2034.
- By distribution channel, the hospital pharmacies segment registered its dominance over the market in 2024.
- By distribution channel, the online drug stores segment is anticipated to grow with the highest CAGR in the market during the studied years.
- By synthesis technology, the liquid phase peptide synthesis (LPPS) segment held a dominant presence in the market in 2024.
- By synthesis technology, the solid phase peptide synthesis (SPPS) segment is set to experience the fastest rate of market growth from 2025 to 2034.
Industry Valuation and Growth Rate Projection
| Industry Worth |
Details |
| Market Size in 2025 |
USD 52.59 Billion |
| Market Size by 2034 |
USD 83.75 Billion |
| Market Growth Rate from 2025 to 2034 |
CAGR of 5.47% |
Introduction Peptide therapeutics are specialized medical treatments that utilize short chains of amino acids known as peptides to address a variety of health conditions. These therapies are designed to mimic or influence natural biological processes, offering an efficient treatment option. Their applications span multiple medical fields, including endocrinology, oncology, and gastroenterology, due to their high specificity and favorable safety profiles.
The global peptide therapeutics market has been experiencing consistent growth. In 2024, the market was valued at approximately USD 49.13 billion and is projected to reach around USD 83.75 billion by 2034, reflecting a compound annual growth rate of 5.31% during this period. This expansion is driven by the increasing prevalence of chronic diseases such as cancer and metabolic disorders, as well as advancements in peptide synthesis technologies. Peptide therapeutics are utilized in various sectors, including hospitals, specialty clinics, and research institutions, highlighting their broad applicability in modern medicine.
- The increasing incidence of conditions like diabetes, cancer, and cardiovascular diseases has heightened the demand for effective and targeted therapies, positioning peptide therapeutics as a vital component in treatment regimens.
- Innovations in synthesis methods, such as solid phase and liquid phase peptide synthesis, have improved the efficiency and scalability of peptide production, facilitating broader clinical applications and fostering market expansion.
Peptide Therapeutics Market: Stats and Figures
- Major pharmaceutical companies are investing in peptide-based treatments for obesity. For instance, Roche and Zealand Pharma have entered into a $5.3 billion agreement to develop Petrelintide, a weekly injectable drug that mimics the hormone amylin, showing significant weight loss results in early trials.
- The increasing complexity of peptide drugs and the need for targeted therapies have led to substantial investments in research and development, aiming to improve the efficient and safety profiles of peptide-based treatments.
How AI has Benefited the Market
- AI models, such as those developed by Gubra, facilitate rapid de novo peptide design, optimizing sequences for desired therapeutic properties and expenditure the transition from concept to candidate selection.
- By analyzing protein expression profiles and genetic variations, AI assists in designing peptide therapeutics that selectively target diseased cells, improving efficacy and minimizing off-target effects.
- AI algorithms evaluate pharmacodynamics properties and safety profiles of peptide drugs, aiding in the design and screening processes to assure optimal therapeutic outcomes.
- Platforms like AlphaFold 3 predict protein structures and interactions, enabling researchers to identify new target pathways for peptide drug delivery.
Industry Leader Announcements
- In a strategic move to improve peptide synthesis technologies, Asahi Kasei Bioprocess America and PeptiSystems announced a global partnership. Karin Granath, CEO of PeptiSystems, stated, “This partnership underscores our shared commitment to delivering transformative and reliable technologies to the peptide synthesis market.”
- Zealand Pharma has been recognized for its strong pipeline portfolio of peptide therapeutics targeting metabolic, gastrointestinal, and cardiovascular diseases. The company’s focus on innovative peptide-based medicines underscores the growing importance of peptides in addressing complex health conditions.
Geographical Insights
North America
North America has established itself as the dominant region in the peptide therapeutics market, accounting for over 45% of the global revenue share in 2024. This leadership is primarily driven by the region’s advanced healthcare infrastructure, significant investments in research and development, and a high prevalence of chronic diseases such as cancer and metabolic disorders. The presence of major pharmaceutical companies and supportive frameworks further bolsters the market’s growth in this region.
Asia Pacific
The Asia Pacific region is projected to experience the fastest growth in the peptide therapeutics market, with a compound annual growth rate of 6.20% between 2025 and 2034. Factors contributing to this rapid expansion include increasing healthcare expenditures, a growing elderly population, and rising awareness of peptide-based treatments. Additionally, the region’s improving healthcare infrastructure and increasing investments in pharmaceutical research are accelerating the adoption of peptide therapeutics.
China
Within the Asia Pacific region, China stands out as a major contributor to the peptide therapeutics market. The country’s significant investments in biotechnology and pharmaceutical research, coupled with government initiatives to modernize healthcare, have led to advancements in peptide drug development. China’s large patient population and increasing demand for innovative treatments further position it as a leader in this sector within the region.
Recent Developments in the Peptide Therapeutics Market:
- In a significant move, Roche and Zealand Pharma have entered into a $5.3 billion agreement to co-develop Petrelintide, a weekly injection obesity drug that mimics the hormone amylin. This partnership aims to expand Roche’s next-generation drug pipeline and positions the companies to compete with dominant players in the lucrative weight loss market.
- Eli Lilly has announced its acquisition of privately held Site One Therapeutics in a deal valued at up to $1 billion. This strategic acquisition grants Eli Lilly access to STC-004, Site One’s experimental non-opioid pain treatment that targets Nav 1.8 channels involved in pain signal transmission. The deal includes an upfront cash payment and additional milestone-based payments to Site One shareholders, contingent on regulatory and commercial achievements.
Competitive Landscape
The peptide therapeutics market is moderately concentrated, characterized by a mix of established pharmaceutical giants and specialized biotech firms. This structure fosters both robust competition and collaborative innovation. Peptide therapeutics are utilized across various medical fields, including oncology, metabolic disorders, and infectious diseases, attracting a wide range of companies.
Company Name: Eli Lily and Company Year of Incorporation: 1876 Headquarters: Indianapolis, Indiana, USA
Eli Lily is a global pharmaceutical company specializing in innovative medicines across various therapeutic areas, including diabetes, oncology, and neuroscience. Lilly’s development of GLP-1 receptor agonists, such as Mounjaro and Zepbound, has positioned it as a leader in the weight loss drug market. The company continues to invest heavily in R&D, focusing on next-generation therapeutics to address unmet medical needs.
- Company Name: Amgen Inc.
- Year of Incorporation: 1980
- Headquarters: Thousand Oaks, California, USA
Amgen is a biotechnology firm committed to unlocking the potential of biology for patients suffering from serious illness. Amgen’s product line includes therapies for oncology, cardiovascular disease, and inflammation.
- Company Name: Pfizer Inc.
- Year of Incorporation: 1849
- Headquarters: New York City, New York, USA
Pfizer is one of the world’s premier biopharmaceutical companies, developing and producing medicines and vaccines across a wide range of disciplines. The company has been actively involved in peptide therapeutics, focusing on innovative solutions to address complex diseases.
